Quick Answer
GoodRx Holdings, Inc. reported Research And Development Expense of $121.03 million for the year ending 2025.
- GoodRx Holdings, Inc. showed a decrease of -2.2% in Research And Development Expense from 2024 to 2025.
- This data is from GoodRx Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $7.84 million | Q1 2020: $10.33 million | Q2 2020: $11.96 million | Q3 2020: $15.85 million | Q1 2021: $26.16 million | Q2 2021: $29.57 million | Q3 2021: $35.07 million | Q1 2022: $35.04 million | Q2 2022: $35.40 million | Q3 2022: $35.92 million | Q1 2023: $32.91 million | Q2 2023: $31.29 million | Q3 2023: $39.61 million | Q1 2024: $31.02 million | Q2 2024: $30.85 million | Q3 2024: $30.14 million | Q1 2025: $31.14 million | Q2 2025: $29.93 million | Q3 2025: $31.01 million.
- Over the full 8 years of available data (2018 to 2025), GoodRx Holdings, Inc.'s Research And Development Expense has grown by 175.7%.
- Historical annual values: Fiscal year 2025: $121.03 million | Fiscal year 2024: $123.75 million | Fiscal year 2023: $135.84 million | Fiscal year 2022: $143.14 million | Fiscal year 2021: $125.86 million | Fiscal year 2020: $61.82 million | Fiscal year 2019: $29.30 million | Fiscal year 2018: $43.89 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: